POTOMAC, Md. - IGC Pharma, Inc.  NYSE American  IGC  has initiated a Phase 2b clinical trial through ClinCloud, a Florida-based clinical research facility, to evaluate the safety and efficacy of IGC-AD1, a drug aimed at treating agitation in Alzheimer s patients.
IGC Pharma has initiated a Phase 2b clinical trial to evaluate the safety and efficacy of IGC-AD1, a drug aimed at treating agitation in Alzheimer's patients. The trial is being conducted through ClinCloud, a Florida-based clinical research facility.